Form 4: CytomX Therapeutics Director Halley E. Gilbert Acquires 38,000 Stock Options
SEC Form 4 Filing
Director Halley E. Gilbert acquired 38,000 stock options in CytomX Therapeutics on May 15, 2024, according to a Form 4 filing.
Summary
- On May 15, 2024, Halley E. Gilbert, a director of CytomX Therapeutics, Inc. (CTMX), acquired 38,000 stock options.
- The exercise price of these options is $1.96.
- The options vest on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- The options expire on May 14, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be interpreted as a sign of confidence, but it doesn't provide enough information to strongly skew positive or negative.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the options is tied to continued service as a director.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction: Halley E. Gilbert acquired 38,000 stock options. |
| 05/15/2025 | Earliest vesting date of the options, assuming continuous service as a director. |
| 05/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.